SMYD3 and neoplasm: Finally, we performed xenograft tumor growth studies using H1092 SCLC cells either depleted for SMYD3 via CRISPR/Cas9 or treated with SMYD3i, with and without CP treatment (Fig. 1F; Supplementary Fig. S1J).